PAR 7.69% 21.0¢ paradigm biopharmaceuticals limited..

I tried to purchase the related report 'Sprifermin Emerging Drug...

  1. 692 Posts.
    lightbulb Created with Sketch. 130
    I tried to purchase the related report 'Sprifermin Emerging Drug Insight and Market Forecast - 2032' but it seems to costs thousands!

    I note two things already which give me hope.

    I read in the link that their injection is intra-articular (into the joint), whereas ours is subcutaneous (under the skin) which I recall Mozz saying is the more comfortable option. (That's right, yes, Mozz?) I didn't see how many injections are required so that could be a deal breaker if results are similar.
    Retreatment is required every 6-12 months, more frequently than ours, again in our favour.

    I think there has been discussion about Sprifermin before on this platform. If anyone remembers where I can find it, I would appreciate your help.


 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.